Press Room

Event

Connect in Pharma 2023

Start

Wednesday, June 14, 2023 - 00:00

End

Thursday, June 15, 2023 - 00:00

Location: Palexpo, Geneva

Hovione presenting at the upcoming “Connect in Pharma” in Geneva.

Connect in Pharma drives innovation, business, and new partnerships in four key areas: Innovative packaging, drug delivery systems, CMO/CDMO, and filling & assembling processes, supporting pioneers in the pharma and biopharma industry. With conferences, workshops and curated networking “Connect in Pharma” offers a platform to drive innovation and solve challenges.

On June 14, José Luís Santos, Director of Technology Intensification will host a session on “The Role of a CDMO in Accelerating the Adoption of Continuous Tableting” and will join a group of experts during a panel discussion on the topic of “Continuous Manufacturing of solid dosage forms: state of the art and future advances”.

Session | The Role of a CDMO in Accelerating the Adoption of Continuous Tableting

Wednesday 14 June, 2:00 PM - 2:30 PM (Theatre 2)

The application of continuous tableting (CT) is steadily developing a foundation in the pharmaceutical industry. Large pharma organizations have been at the forefront of adoption due to their evolving development pipelines that justify the technological disruption. However, systemic application of CT requires more than individually owned installations and can only be achieved with the partnership of the health authorities, equipment vendors, and contract development and manufacturing organizations (CDMOs).

A CDMO role is particularly important for the adoption of emerging technologies such as CT, in that an equipment standard needs to be established where most of the industry can seamlessly integrate with their own development, manufacturing, and supply chains. The processes and knowledge of owning and operating the technology must be broad, yet robust, to assure that the benefits outweigh the perceived risks by a meaningful margin.

This talk will focus on the key areas that require attention for the adoption of CT by the industry, and how at Hovione we are setting ourselves up for successful deployment of the technology.

Panel Discussion | Continuous Manufacturing of solid dosage forms: state of the art and future advances

Wednesday 14 June, 3:30 PM - 4:00 PM (Theatre 2)

We look forward to seeing you in Geneva.

Find out today if Continuous Tableting is right for your product.

Connect with our experts and get to know more about the distinct set of features and advantages that allows going from development to manufacturing in record time with high quality and less variability.

The future is continuous.

Let’s discuss your project together.

Find more about Connect in Pharma.

Also in the Press Room

See All

Twenty companies presented at the annual kickoff to DCAT Week. The Drug, Chemical & Associated Technologies Association (DCAT) opened DCAT Week 2026 with its Member Company Announcement Forum. The kickoff to the annual event in New York City, underway from March 23–26, 2026, showcased 20 companies. These were selected based on their announcements’ “news priority, criticality, and interest” to DCAT member companies. The following is a summary of highlights from the presentations, supplemented by additional information provided by some of the companies. (...) Hovione Hovione’s Vice President of Technical Operations for the Americas, David Basile, delivered the company’s Member Company Announcement Forum presentation. Basile will be speaking exclusively with Contract Pharma during DCAT Week, so check back for more on Hovione’s latest. Read the full article at ContractPharma.com

Press Clipping

Contract Pharma, 23 March 2026

DCAT Member Company Announcement Forum 2026: An Inside Look

Mar 23, 2026

With more than six decades of experience in pharmaceutical development and manufacturing, Hovione is an international CDMO offering a comprehensive range of services for New Molecular Entities (NMEs), including drug substances, intermediates, and drug products. The company also supplies niche generic APIs and delivers advanced technologies supporting multiple drug delivery platforms, including oral, injectable, inhalation, and topical formulations. Today, Hovione employs 2,500 people worldwide and operates 900 m3 of manufacturing capacity across four sites in Europe, the U.S. and Asia. Japan has played an important role in the company’s global strategy since its early years. Initial export activities were followed in 2017 by the establishment of a Japanese subsidiary in Osaka. Read the full article in Japanese at Yakuji.co.jp Read the article translated in English

Press Clipping

Yakuji Nippo Magazine, 13 March 2026

International CDMO strengthens its presence in Japan: from active pharmaceutical ingredients to formulations, all at the same location

Mar 13, 2026

In an interview with Executiva, a portuguese media outlet focused on women´s leadership, Diane Villax, co-founder and long-standing leader of Hovione, reflects on her journey and the company’s development over more than six decades. Diane Villax’s career began at a time when few women worked outside the home. At 19, she joined a trading company as a foreign languages correspondent, where she developed essential business skills — including commercial correspondence, banking and export procedures — that later proved instrumental in helping her husband, Ivan Villax, establish Hovione in 1959. From its earliest days operating in the family home in Lisbon, Hovione adopted an international outlook. The company’s first major customers were in Japan, setting demanding quality standards that helped shape its long-term position in global markets. Over the following decades, Hovione expanded its footprint with the construction of its first manufacturing site in Loures (1969), followed by expansion to Macau (1986), the United States (New Jersey, early 2000s) and Ireland (Cork). The company grew into a global organization with more than 2,500 employees — including over 300 scientists — and a reputation as a preferred supplier to leading pharmaceutical companies worldwide. Throughout the interview, Diane highlights the values that have guided the company’s development: a commitment to excellence, a strong work ethic, and a focus on quality and long-term relationships. Although she did not have formal business training, she learned “on the job” and brought discipline, precision and structure to her role — particularly in the company’s early financial and administrative leadership. Now in her nineties and an active member of Hovione’s Board of Directors, Diane Villax remains engaged with the company’s evolution and governance, reflecting a continued commitment to its long-term development. Her story reflects entrepreneurial drive, resilience and long-term leadership — and offers insight into the values that have shaped Hovione’s trajectory for more than six decades. Read the full interview at Executiva.pt (in portuguese).

Article

Executiva, 23 February 2026

Hovione’s Diane Villax: “I was not brought up to be a business woman”

Feb 23, 2026

Also in Events

See All

Browser not supported